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1. Introduction 
1.1 Gliomas 
Gliomas are the most common primary brain tumors in the human central nervous 
system [1] and constitute approximately more than 70% of all brain malignant tumors 
[2]. According to the World Health Organization (WHO), gliomas are classified into 4 
malignant grades (from I to IV) by histological criteria. Glioblastoma multiforme 
(GBM, WHO grade IV), the most aggressive glioma type, accounts for more than half 
of gliomas [3]. In the past decades, despite large efforts in surgery, chemotherapy, 
radiotherapy and tumor biology, there is still no substantial improvement of the 
overall 5 year survival rate [4]. 
  
1.1.1 Symptoms of gliomas 
The different affected positions in the central nervous system cause various symptoms 
of gliomas. Occasionally tumor only causes asymptomatic condition, but mostly 
tumor can cause symptoms fast when it grows into an huge size. The brain glioma can 
lead to increased intracranial pressure and eventually result in vomiting, cranial nerve 
disorders, headaches and seizures [5]. The spinal cord glioma results in numbness, 
pain or weakness of extremities. The optic nerve glioma can lead to visual loss. 
Gliomas usually metastasize through the cerebrospinal fluid instead of spreading via 
the bloodstream, and subsequently produce“drop metastases”in the spinal cord.    
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1.1.2 Glioblastomas  
Glioblastoma (GBM) is an astrocytic tumor and is considered as extremely malignant, 
there is an incidence rate of 3.19 per 100,000 which occurs in average at an age of 64 
years [6]. It represents approximately 15% of primary intracranial tumors and is 
classified as the Grade IV tumor by World Health Organization [7]. The main 
histopathological characteristics of GBM are necrosis, cellular polymorphism, 
microvascular proliferation, and brisk mitotic activity. The whole prognosis of 
patients who have GBM stays grim, although there are improvements in multi-modal 
treatment options and imaging techniques. It is estimated that despite maximal 
treatment, the median duration of survival is only 12 to 18 months. However, patients 
who have no intervention die shortly after diagnosis [8, 9]. So far, there are only small 
number of cases with long-term survival or other curative outcomes that have been 
reported [10, 11].  
 
1.1.3 Glioma therapy 
There are different strategies for glioma therapy which depend on the location of 
tumor, the grade of malignancy and the cell type. For high grade glioma the treatment 
usually is a combined therapy, comprising surgery, chemotherapy and radiotherapy 
[12]. To patients who have glioblastoma presenting with positive neurologic 
performance status, the present standard treatment includes maximum safe surgical 
resection with subsequent adjuvant radiotherapy and concurrent temozolomide 
application [13]. As humanized recombinant monoclonal antibody against vascular 
endothelial growth factor (VEGF), named Bevacizumab has been approved for the 
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treatment of recurrent glioblastoma [14, 15].  
Though substantial efforts were made in medical technology, the approaches for high 
grade gliomas are still only palliative [16]. It was suggested to make classification for 
high grade glioma according to the tumor mass gene expression-profile, and the 
resulting GBM subtypes were named proneural, neural, classical or mesenchymal 
[16-18]. It may make the therapy more individualized and efficient for patients 
according to the GBM genetic classification in the future. 
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1.2 Pericytes 
1.2.1 Definition of pericyte 
Pericytes as a new cell type were discovered by Charles Rouget in 1873, and were 
called Rouget cells in the beginning and renamed pericytes later [19]. Pericytes 
display a perivascular morphology and usually wrap themselves around blood vessels 
[20]. Most peripheral pericytes are regarded as arising from the mesoderm, 
nevertheless others originate from the neural crest, for example brain pericytes [21]. 
Usually pericytes are located on the surface of capillaries, they interact with  
endothelial cells which are situated on the same basement membrane [22]. Pericytes 
have similar features with vascular smooth muscle cells: they are capable of 
regulating vasomotion and containing contractile filaments consist of alpha- smooth 
muscle actin (αSMA) and vimentin [19]. The density of pericytes also varies in 
different area of the body, which is already shown to correlate with the blood pressure 
levels [23]. It is generally considered that the vasculature of central nervous system 
(CNS) is covered by most pericytes with a ratio of 1:3-1:1 between pericytes and 
endothelial cells. Moreover, the coverage is up to approximately 30% on the 
abluminal surface [24, 25].The highest coverage of pericytes can be detected in the 
brain and retina which is probably related to the regulation of tight endothelial barrier 
[26].  
 
 
1.2.2 Protein and receptor expression on pericytes 
Pericytes express a certain range of proteins and receptors, which are considered as 
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markers for pericytes. The membrane markers include neuron-glial 2 (NG2), CD146, 
platelet-derived growth factor receptor β (PDGFRβ), endoglin and aminopeptidases A 
and N (CD13) [27-29]; cytosolic markers include desmin, vimentin and nestin (table 
1.2). Routinely these markers are used to identify pericytes, however, they are not 
expressed by pericytes in every organ or tissue and neither one of them is completely 
specific. It could be due to the plasticity of pericytes, since different markers can be 
expressed by pericytes in different organs and tissues at different developing stages 
[30]. 
 
Table 1.2 Cytosolic and membrane-bound markers for the identification of 
vascular mural cells [19] 
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1.2.3 Pericyte function 
I The role of pericytes in blood-brain-barrier (BBB) 
In the central nervous system, pericytes are components of a complex structure called 
neurovascular unit (NVU) which consists of neurons, endothelial cells, microglial 
cells and astrocytes [31]. The role of astrocytes has been well described in BBB 
regulation, and it also has been reported that NVU pericytes were involved. During 
embryogenesis, recruitment of pericytes is essential for BBB formation, and the 
coverage of pericytes is considered as a crucial factor for vascular permeability 
[32]. Bell and colleagues reported vivo evidences that proves the pericyte- 
involvement in BBB, they suggested that BBB breakdown, the accumulation of 
macro- molecules and toxic serum proteins were related to the decrease of pericyte 
coverage [33]. Pericytes are regarded as being capable of controlling blood flow and 
trans-endothelial transport, therefore pericytes can play an important role in 
blood-brain barrier formation and its functionality [34]. 
 
 
II Angiogenesis 
Pericytes play an essential role in vessel formation, stabilization and remodeling [35]. 
There are several factors and signaling pathways suggested to play a significant role 
in intercellular communication between endothelial cells and pericytes, such as 
platelet-derived growth factor B (PDGF-B), angiopoietins, transforming growth 
factorβ (TGFβ) and spingosine-1-phosphate [26, 30, 36]. In genetically modified 
mouse models, the significance for the signaling pathway of PDGF-B/PDGFRb has 
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been greatly emphasized [37]. PDGF-B is considered to have the high affinity to bind 
with PDGFRb and PDGFRb is abundant on pericytes. Sprouting endothelial cells can 
produce PDGF-B during angiogenesis promoting the attachment and recruitment of 
pericytes [38]. Impaired PDGF-B/PDGFRb signaling can lead to unsuccessful 
pericyte recruitment and decreased microvascular coverage of pericytes, which finally 
results in endothelial hyperplasia, formation of microaneurysms and abnormal 
vascular morphogenesis [39]. Genetic deletion of PDGF-B or PDGFRb can lead to 
perinatal death because of vascular dysfunction [40, 41]. When investigating the 
coverage of pericytes in the retina of genetically modified mice, a decreased amount 
of pericytes has been discovered and leaded to serious hemorrhage [42]. The 
significance of PDGF-B is highlighted in many studies, which demonstrate that 
PDGF-B ablation can lead to decreased retinal pericytes coverage resulting in altered 
capillary diameter, microaneurysms and regressing capillary branches [43]. We can 
conclude that the well-controlled and balanced secretion of endothelial PDGF-B plays 
an important role in developing and maintaining the vasculature in CNS. 
 
III Contractile function 
In larger vessels VSMCs play an essential role in vasodilatation and vasoconstriction, 
while in the capillaries pericytes have great effect on regulating vascular diameter. As 
pericytes are located on the surface of capillaries and express contractile proteins, so 
the pericytes are suggested to take part in the regulation of microvascular blood flow 
[44]. Fernández-Klett demonstrated that in vivo pericytes are able to regulate blood 
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flow in capillaries of the brain cortex [45]. It was suggested that pericytes might be 
playing a role as pre-capillary sphincters, since the contractile proteins are abundantly 
located in the transitional position of arterioles and capillaries [46]. The vessel 
diameter can be influenced by different vasoactive circulatory ligands through 
activating pericyte cell-surface receptors. For example, endothelin-1, angiotensin 2, 
histamine and serotonin can produce vasoconstriction, whereas β2-adrenoceptors, 
cholinergic agonists and nitric oxide can produce vasodilation [47]. These findings are 
in accord with the theory that the contractility of pericytes contributes to the 
microvasculature blood flow regulation. 
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1.3 Aims of the study 
Pericytes are considered as a component of the vessel structure and they play an 
important role in blood-vessel formation and maintenance, but the role of pericyte 
progenitor cells was not studied previously because they were not discovered. In this 
study we established a NesCreER
T2
-Ai9tdTomato double transgenic mouse model that 
allowed tracing the fate of nestin-expressing cells in high-grade glioma and 
tumor-free brain over postnatal period, the pericyte progenitor cells were investigated 
in the current study.  
 
 
The aim of this study: 
 
(1) To trace cells of the pericyte-lineage throughout glioma angiogenesis in vivo; 
(2) To trace cells of the pericyte-lineage throughout postnatal brain development; 
(3) To compare the cell populations identified with different nesCreER
T2
-mouse 
models; 
(4) To trace cells of the pericyte-lineage in the developing vasculature of the retina. 
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2. Materials  
2.1 Technical equipment 
Table 2.1 Technical equipment 
Lab appliance Company 
Balances-MonoBloc Mettler Toledo 
Balances-AG204 Mettler Toledo 
Centrifuge Thermo Fisher Scientific GmbH 
Fridge (-4℃ ,-20 ℃) LIEBHERR GmbH 
Fridge (-80 ℃) LIEBHERR GmbH 
Hera safe hood Thermo Fisher Scientific GmbH 
Incubator Kendro GmbH 
Laboratory Labeling system LABXPERT TM 
Microscope (fluorescence) -Axiovert 25 Carl Zeiss Microscopy GmbH 
Microscope (transmitted light) - Axioskop 2 Carl Zeiss Microscopy GmbH 
Microscope (confocal) TCS SP5 Leica Microsystems Vertrieb GmbH 
Microscope camera- AxioCam MRm ZEISS GmbH 
Microtome Slide 2003 PFM medical AG 
Magnetic Hotplate Stirrer  VWR International GmbH 
Perfusion system-Dose IT P910 Integra Biosciences AG 
Pep-pen Dako GmbH 
Pipette boy Eppendorf GmbH 
Pipettes Eppendorf GmbH 
Shaker Biozyme Scientific GmbH 
12- and 24-well plates TPP Techno GmbH 
17 
 
2.2 Consumables 
Table 2.2 Consumables 
Product Supplier 
Tubes (0.5ml,1ml,2ml) Eppendorf GmbH 
Tubes (15ml,50ml) VWR GmbH 
Pipette tips (10μl, 20μl, 200μl ,1000 μl) Eppendorf GmbH 
Slide for immunolabelling Gerhard Menzel GmbH 
cover slips Gerhard Menzel GmbH 
Plate (12 wells,24 wells) TPP GmbH 
Tissue-Tek Cryomold 
(15mm×15mm×15mm) 
Sakura Finetek USA 
 
 
2.3 Reagents and Chemicals 
Table 2.3 Reagents and Chemicals 
Product Supplier 
Acetone100% Sigma GmbH 
Antibody diluent Dako  
CIdu-C6891(5-Chloro-2’-deoxyuridine) Sigma GmbH 
Corn oil Sigma GmbH 
DAPI Sigma GmbH 
DAB-DC135c006 DCS Labline 
DAB-substrate-PC136R100 DCS Labline 
Donkey serum  Sigma GmbH 
Dual Endogenous Enzyme block Dako 
Ethanol-70% CLN GmbH Chemikalien Laborbedarf 
18 
 
Ethanol-96% CLN GmbH Chemikalien Laborbedarf 
Ethanol-100% CLN GmbH Chemikalien Laborbedarf 
Eosin G-solution  Sigma GmbH 
Ethylene Sigma GmbH 
Cryomatrix Thermo Sientific 
Glycerol Sigma GmbH 
Goat serum Sigma GmbH 
Hope DCS Labline  
Hemalaun Carl Roth GmbH 
Idu-17125 (5-iodo-2’-deoxyuridine) Sigma GmbH 
ketamine Zoetis Deutschland GmbH 
0.9%Nacl  B.Braun Melsungen AG 
2%Rompun Bayer Vital GmbH 
Mounting Medium IBIDI GmbH 
PBS Apotheke Klinikum der Universität 
München 
Paraformaldehyde (PFA) Sigma GmbH 
Protein Block Dako GmbH 
Sucrose Sigma GmbH 
Tamoxifen-T5648 Sigma GmbH 
Triton X-100 Roche Diagnostics GmbH 
Tween-20 Sigma GmbH 
Xylol Sigma GmbH 
X-gal Thermo Fisher 
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2.4 Immunohistochemistry 
2.4.1 Primary Antibodies 
Table 2.4.1 Primary Antibodies 
Immunogen Host 
Species 
Isotype Catalog 
number 
Dilution Provider 
NG2 Rabbit IgG ab5320 1:200 Millipore AG 
Desmin Rabbit IgG ab15200 1:200 Abcam,  
SOX2 Rabbit IgG Ab97959 1:200 Abcam 
PDGFRß Goat lgG AF1042 1:200 R+D GmbH 
CD146 Rabbit IgG Ab75769 1:800 Abcam 
CNpase mouse IgG Ab6319 1:250 Abcam 
RFP Rabbit IgG ab62341 1:200 Abcam,  
Iba1 Rabbit IgG 019-19741 1:500 Wako GmbH 
GFAP Rabbit IgG Z0334 1:500 Dako 
CD31 Rat IgG 550274 1:50 Cat 
CD45 Rat IgG 110-93609 1:100 Novus-USA 
VWF Rabbit IgG A0082 1:400 Dako GmbH 
IB4- 
biotinylated 
  B-1205 1:100 Vector 
IB4-FITC   L-2895 1:200 Sigma 
β-gal Rabbit IgG A11132 1:300 Molecular 
Probes 
SMA Rabbit IgG ab66133 1:400 Abcam 
S-100ß mouse IgG S2532 1:500 Sigma 
 
 
 
 
 
20 
 
2.4.2 Secondary antibodies 
Table 2.4.2 Secondary Antibodies 
Antigen Host 
Species 
Conjugation Catalog 
number 
Dilution Provider 
Rabbit 
IgG 
Donkey Alexa Fluor 
488 
711545152 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Rabbit 
IgG 
Donkey Alexa Fluor 
594 
711585152 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Rabbit 
IgG 
Donkey Cy3 71116152 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Rabbit 
IgG 
Donkey biotinylated 711065152 1:250 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Goat IgG Donkey biotinylated 705065147 1:250 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Goat IgG Donkey Alexa Fluor 
488 
705545147 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Goat IgG Donkey Cy3 705165147 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Rat IgG Donkey biotinylated 712065153 1:250 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
21 
 
 
 
 
 
 
 
 
2.4.3 Streptavidin-conjugated fluorophores 
Table 2.4.3 Streptavidin-conjugated fluorophores 
Fluorescence Catalog 
Number 
Dilution Provider 
Alexa Fluor 488 016540084 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Alexa Fluor 594 016580084 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Alexa Fluor 647 016600084 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Streptavidin-HRP SA-5004 1:200 Vector  
 
 
 
 
 
 
 
Mouse 
IgG 
Donkey Cy5 715175150 1:500 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
Chicken 
IgG 
Donkey biotinylated 703065155 1:250 Jackson 
Immuno- 
Research,  
West Grove, 
PA, USA 
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2.5 Software 
Table 2.5 Software 
Software  Provider 
Microsoft office 2007 Microsoft  
GraphPad Prism 6 Graph Pad Software 
Image J National Institutes of Health, USA 
Adobe Illustrator CS6 Adobe Systems 
Adobe Photoshop CS6 Adobe Systems 
Windows 7 system Microsoft 
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3. Methods 
3.1 Mouse models 
In this study we used NesCreER
T2
 and Ai9tdTomato double transgenic mouse models. 
As an essential tool for the generation of conditional mouse mutations, the Cre/loxp 
recombination system is used for the induction of a permanent reporter achieved by 
the red fluorescent protein td-Tomato. Cre can recombine the gene sequence between 
two 34-bp DNA recognition sites which are called loxP sites. The animals used in this 
study express Cre recombinase under the control of the nestin promoter [48]. The 
nestin gene is active in neural stem cells and also other progenitor cells during the 
development of the central nervous system (CNS) [49]. CreER, a fusion protein of 
Cre and the human estrogen receptor, is tamoxifen inducible. Without tamoxifen 
CreER will stay in cytoplasm and has no function, but it becomes activated by 
tamoxifen administration. After being activated, the CreER will be translocated into 
the nucleus and recombine the gene sequence of loxP-flanked sites [50]. The reaction 
of CreER
T2
 with tamoxifen is more efficient than Cre-ER
T 
[51], thus, the mice with 
the expression of CreER
T2
 under the control of nestin promoter can provide a helpful 
tool for investigating progenitor cells in physiology and pathology of the brain. When 
NesCreER
T2
 mice and Ai9-tdTomato mice are crossed generating NesCreER
T2 
x 
Ai9tdTomato mice, tamoxifen administration will activate Cre recombinase and can 
excise a floxed stop cassette and will disinhibit the expression of RFP. As a result, 
RFP as a reporter molecule can be used as a fate-mapping tool for nestin- expressing 
cells in NesCreER
T2
 x Ai9tdTomato mice. 
24 
 
 
 
Fig. 3.1 The NesCreERT2-Ai9tdTomato mouse model  
(Modified from http://www.ics-mci.fr) 
 
For all mouse treatments, we followed the rules and regulations of the Regierung Von 
Oberbayern according to the animal protection act. All the mouse experiments were 
performed in the Walter Brendel Centre of the Klinikum Groβhadern LMU.  
 
In this study, the NesCreER
T2
 x Ai9tdTomato transgenic mice were used. There were 
3 experiment mouse groups, all mice carried both the NesCreER
T2
 and the 
Ai9tdTomato transgene. the mice in each group were inoculated 1X10
5
 GL261(1ul) 
glioma cells on day 0 and administrated with tamoxifen on day 4-6, the tumor growth 
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was observed over a time course (7 days,14 days and 21 days).  
As controls, there were 3 further mouse groups: negative control group 1, negative 
control group 2 and positive control group 3. The mice in each group were inoculated 
1X10
5
 GL261 (1ul) glioma cells on day 0 and sacrificed at day 14, they were 
genetically modified as following:  
Negative control group 1: nes-CreER
T2
 (–); Ai9-tdTomato (+); TAM i.p. on 4-6d;  
Negative control group 2: nes-CreER
T2
 (+); Ai9-tdTomato (+); TAM i.p. (–);  
Positive Control group 3: nes-CreER
T2
 (+); Ai9-tdTomato (+); TAM i.p. on 4-6d;  
To further investigate the lineage of nestin positive cells in the NesCreERT2- 
tdTomato mouse strain, gene recombination was induced after birth (at postnatal day 
0; po), and the mice were sacrificed after 3 weeks (p21).  
Furthermore, another mouse model named Jnes-CreER
T2
 were also used in this study 
(the transgenic nestin-promoter element in Jnes-CreER
T2
 is different from the 
Nes-CreER
T2
). the mice were inoculated 1X10
5
 GL261(1ul) glioma cells on day 0 and 
administrated with tamoxifen on day 4-6, the tumor growth was observed over a time 
course (14 days and 21 days). 
 
3.1.1 Tumor cells inoculation 
1. Anesthesia 
Preparation of narcotic 
10% Ketamine 1.02ml 
2% Rompun 0.36ml 
0.9% Nacl 4.86ml 
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Mice received the narcotic according to body weight (7μl/g) by intra-peritoneal 
injection (i.p), and the eyes were protected with Bepanthen. 
2. Tumor cells inoculation. 
After anesthesia, mice were fixed on the stereotactic frame in a flat-skull position, 
then disinfection was performed with 10% potassium iodide solution, the skin of the 
skull was incised carefully with the scalpel. The accurate inoculation position (1,5mm 
anterior of the bregma; 1.5mm right of the bregma) was confirmed by Vernier Caliper, 
the skull point was drilled carefully by a 21-gauge needle tip. 1X10
5
 GL261 (1 ul) 
glioma cells were injected at a depth of 3mm from the skull surface. Then the 
syringe-needle was retreated slowly about 1 mm/1 min. After the needle was 
completely retreated out, the incision was carefully sutured. 
 
3.1.2 Tamoxifen administration 
Preparation of tamoxifen 
Tamoxifen (T5648,Sigma)   20mg Corn oil (C8267,Sigma)   1ml 
Mice were given tamoxifen according to body weight (75mg/kg) by intra-peritoneal 
injection (i.p) every 24 hours for 3 days. 
 
3.1.3 CIdu and Idu administration 
Preparation of CIdu and Idu 
5-Chloro-2’-deoxyuridine (CIdu)  8.55mg 0.9% NaCl 1ml 
5-iodo-2’-deoxyuridine (Idu)    11.35mg PBS (0.1M)+5N NaOH 2 drops/10 ml PBS, 1ml 
Mice were given CIdu 48 hours before sacrifice according to body weight 
(42.75mg/kg) by intraperitoneal injection (i.p); and Idu (56.75mg/kg) 5 hours before 
sacrifice also by i.p. 
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3.1.4 Sacrifice and perfusion of mice 
First mice were injected with a narcotic according to body weight (7μl/g) by 
intraperitoneal injection (i.p), and then perfused by perfusion system (8.7mL/min) 
through the heart with 20ml PBS and 4%PFA 10ml.  
3.1.5 Fixation and tissue harvest  
Brains were immersed in 4%PFA for 48 hours at +4°C, followed by incubation in 30% 
sucrose for 48 hours at +4°C; brains were embedded in Cryomatrix (ThermoSientific) 
and frozen. Tissue was cut into 40μm sections with a microtome, and stored in 
24-well plates filled with cryoprotectant (Glycerol 125ml+Ethylene glycol 
125ml+Phosphate buffer 250ml) at -20°C. 
3.2 Immunohistochemistry (IHC) 
Immunohistochemistry technology is widely used to label Specific molecular markers, 
it depends on the principle that an antibody can specifically bind to antigens. In this 
study, we mainly perform Immunofluorescence staining. 
 
3.2.1 Immunofluorescence staining for free-floating sections 
Part 1: without biotinylated- Streptavidin Conjugation  
The free-floating sections were usually applied in 24-well plates filled with 
cryoprotectant at -20°C. First we transferred 3-5 sections to a new 12-well plates with 
PBT (PBS+0.1%TWEEN-20), and washed the sections for 3 times for 5 minutes on 
an orbital shaker; And next the sections were incubated with Dual Endogenous 
Enzyme block (S2003, Dako) for 20 minutes (room temperature) to block the 
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endogenous peroxidase; After that the sections were washed 3 times with PBT and 
then incubated with protein block (X0909, Dako) for 1hour (room temperature); After 
then the sections were incubated with primary antibody diluted in Antibody diluent 
(S3022, Dako) overnight at +4°C; The next day, the sections were washed 3 times 
with PBT and subsequently incubated with secondary antibody diluted in Antibody 
diluent (S3022, Dako) for 2 hours (room temperature); Afterwards the sections were 
washed 3 times with PBT again and incubated with Alexa-Hoechst (dillution1:1000) 
for 1 minute (room temperature); At last, the sections were carefully mounted on the 
slide and covered with fluorescence mounting medium. 
 
Part 2: with biotinylated- Streptavidin Conjugation  
First the sections were transferred to a new 12-well plates with PBT 
(PBS+0.1%TWEEN-20) and washed for 3 times for 5 minutes on an orbital shaker; 
And next the sections were incubated with Dual Endogenous Enzyme block (S2003, 
Dako) for 20 minutes (room temperature) to block the endogenous peroxidase; After 
that the sections were washed 3 times with PBT and then incubated with protein block 
(X0909, Dako) for 1hour (room temperature); After then the sections were incubated 
with primary antibody diluted in Antibody diluent (S3022, Dako) overnight at +4°C; 
The next day, the sections were washed 3 times with PBT and subsequently incubated 
with secondary antibody with biotinylated Conjugation diluted in Antibody diluent 
(S3022, Dako) for 3 hours (room temperature); Afterwards the sections were washed 
3 times with PBT again and incubated with Alexa Fluor 488/594/674 with 
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Streptavidin Conjugation diluted in Antibody diluent (S3022, Dako) for 2 hours (room 
temperature); And then the sections were washed 3 times with PBT again and 
incubated with Alexa-Hoechst (dillution1:1000) for 1 minute (room temperature); At 
last, the sections were carefully mounted on the slide and covered with fluorescence 
mounting medium. 
 
3.3 Quantification and analysis  
To evaluate the staining, microscopes (include fluorescence microscope and confocal 
microscope) were applied. 
Fluorescence microscopy 
For the immunofluorescence staining, a fluorescence microscopy (with the 
wavelength range 340-700nm) was used. 
Confocal Microscopy  
Confocal microscopy was also called confocal laser scanning microscopy (CLSM), it 
is able to collect image sets from different depths of the thick sections, from which it 
can reconstruct the three-dimensional structures. It is widely used to analyze the 
co-localization by setting different channel parameter. 
 
All the quantifications were performed using a 20X magnification adjective. For the 
brain sections with tumor, usually 3 areas within tumor were randomly selected; 2 
areas both in peritumoral area and contralateral tumor free area were randomly 
selected. For the tumor free sections, 4 areas were randomly selected from both cortex 
30 
 
sides, brain stem and the area near sub-ventricular zone. Each quantification was 
performed manually according to the pictures under the applying of ImageJ software. 
The software of GraphPad Prism 6 was used for the statistical analysis including 
unpaired t-tests. 
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4. Results 
4.1 RFP expression in the NesCreER
T2
-tdTomato mouse model 
In this study we used the NesCreER
T2
 x Ai9tdTomato mouse model expressing RFP 
as a fate-mapping marker for nestin positive cells. In order to investigate the 
expression of RFP in the mouse brain, cells which are RFP positive were quantified 
on brain sections of glioma-inoculated and tumor-free mice. 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 RFP expression in the NesCreER
T2
 x Ai9-tdTomato mouse model.  
a. RFP positive cells were observed in the tumor area over a time course (7 days, 14 
days and 21 days); b. Quantification of RFP positive cells in the tumor area: The 
number of RFP positive cells increases significantly from 7 days to 14 days and 21 
days (p < 0,01 for all groups); c. RFP positive cells were observed in the tumor area in 
a control group (growth time: 14 days); d. Quantification of RFP positive cells in the 
tumor area: The number of RFP positive cells in negative control groups was 
significantly lower as compared to the experimental group (p< 0,001), but the number 
of RFP positive cells between the two negative control groups showed no difference. 
Scale bars in a,c, 100 µm. 
b 
d 
a 
c 
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There were 3 experiment mouse groups, the mice in each group were inoculated 
1X10
5
 GL261(1ul) glioma cells on day 0 and administrated with tamoxifen on day 
4-6, the tumor growth was observed over a time course (7 days,14 days and 21 days). 
The number of RFP positive cells in the tumor area increases significantly from 7 
days to 14 days and 21 days (Figure 4.1B, p < 0.01). After 21 days, the vast majority 
of RFP positive cells consistently appear perivascular-like. Besides the tumor area, 
RFP positive cells were also observed in peritumoral areas and the contralateral 
hemisphere, but here the number of RFP positive cells was much lower than in the 
tumor area (not shown). Hence, the traced cells of the nestin positive lineage are 
mainly located in the tumor area.  
There were 3 groups of experimental control: Negative control group 1, negative 
control group 2 and positive control group 3 (Figure 4.1C). Few RFP positive cells 
could be observed in the negative control groups (control group 1, 2) in the tumor area, 
while a large number of RFP positive cells are visible in the positive control group 3. 
This indicates that the nes-CreER
T2
 tdTomato mouse model used in the present study 
allows specific cell tracing and has very little endogenous leakiness (the 
Cre-independent RFP expression or the entry of tamoxifen-independent Cre 
recombinase to the nucleus). 
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4.2 Immunohistochemical characterization of the NesCreER
T2
-tdTomato mouse 
model 
The morphology and location of RFP-expressing cells indicated that there is genesis 
of pericytes from the nestin positive linage. The brain tissue was stained with pericyte 
markers such as NG2, CD146, PDGFRß or desmin, and the analysis of co-localization 
of RFP positive cells with the pericyte markers was performed by confocal 
microscopy.  
4.2.1 Immunostaining for NG2 
Neuron-glial 2 (NG2) was abundantly expressed by pericytes during the stage of 
vascular morphogenesis [52, 53]. Not only pericytes but also the GL261 glioma cells 
express NG2 resulting in an extensive intratumoral staining. To test NG2 expression 
in RFP positive cells over the time course of tumor development, mouse brain 
samples from different groups (7 days, 14 days, 21 days) were immunostained and 
analyzed (Figure 4.2.1 a). Confocal picture analysis showed that NG2 staining 
co-localized with RFP positive cells (Figure 4.2.1b). The number of RFP positive cells 
and RFP&NG2 double positive cells was also quantified. The date revealed that 
during tumor progression from 7 days to 14 days and to 21 days, the number of RFP 
positive cells and RFP&NG2 double positive cells increased (Figure 4.2.1c). After 7 
days of tumor progression, few RFP-expressing cells co-localized with NG2, whereas 
after 21 days of tumor growth most of the recombined cells co-localized with NG2, 
which indicated that the pericyte progenitor cells (RFP positive and NG2 negative) 
differentiate into pericytes (RFP positive and NG2 positive) during glioma expansion. 
Compared to the total amount of RFP expressing cells in the tumor, the percentage of 
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RFP&NG2 double positive cells significantly increased from 7.58% (7 days) to 18.61% 
(14 days) and 74.12% (21 days). This indicates that the traced cells from the nestin 
positive lineage develop into pericytes during glioma expansion (Figure 4.2.1d, e). 
The longer the time of tumor growth, the more RFP positive cells expressing pericyte 
markers were detected. Very few RFP&NG2 double positive cells were observed in 
peritumoral areas and the contralateral hemisphere (Figure 4.2.1 f, g), which indicates 
that new pericytes derive from pericyte progenitors of the adult brain most 
prominently during neo-angiogenesis. 
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Figure 4.2.1 NG2 expression in the NesCreERT2 TdTomato mouse model. 
a. RFP (shown in red) and NG2 (shown in green) expression in the tumor area of the 
NesCreER
T2
-tdTomato glioma mouse model is shown at different time points of tumor 
expansion (7 days and 21 days, 14 days not shown); b. Confocal microscopy indicated that 
NG2 co-localized with RFP-expressing cells: after 7 days, there were very few RFP positive 
cells co-localized with NG2, but after 21 days, most RFP positive cells co-localized with NG2, 
which indicated that the pericyte progenitor cells (RFP positive and NG2 negative) 
differentiate into pericytes (RFP positive and NG2 positive) during glioma expansion; c. RFP 
positive cells and RFP&NG2 double positive cells in tumor area were quantified; d, e. The 
percentage of RFP&NG2 double positive cells accounting for the total RFP positive cells was 
calculated (p<0.01); f, g. RFP positive cells and RFP&NG2 double positive cells in 
peritumoral areas and contralateral hemisphere were quantified. Scale bars in a,b, 50 µm. 
a b 
c d e 
f 
g 
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4.2.2 Immunostaining for CD146 
Cluster of differentiation marker 146 (CD146) is a transmembrane glycoprotein and 
constitutes another membrane bound marker for pericytes [52]. Similar to the NG2 
analysis (see above), mouse brain samples from different groups (7 days,14 days,21 
days) were stained and analyzed (Figure 4.2.2 a). Confocal pictures showed that 
CD146 staining also co-localized with RFP positive cells after 21 days (Figure 4.2.2b).  
RFP positive cells and RFP&CD146 double positive cells were also quantified. The 
number of RFP positive cells significantly increased from 7 days to 21 days, after 7 
days, there were very few RFP positive cells co-localized with CD146, but after 21 
days, most RFP positive cells co-localized with CD146, the percentage of 
RFP&CD146 double positive cells accounting for RFP-expressing cells significantly 
increased from 19.62% (7 days) to 53.88% (14 days) and 83.46% (21 days). (Figure 
4.2.2 d, e), which indicated that the pericyte progenitor cells (RFP positive and 
CD146 negative) differentiate into pericytes (RFP positive and CD146 positive) 
during glioma expansion. Also, in the peritumoral areas and contralateral hemisphere, 
very few RFP&CD146 double positive cells were observed (Figure 4.2.2 f, g). The 
percentages of RFP&CD146 double positive cells accounting for RFP-expressing 
cells at 7 days, 14 days and 21 days are similar to the percentages of RFP&NG2 
double positive cells: after 7 days, there were very few RFP positive cells co-localized 
with CD146 or NG2, but after 21 days, most RFP positive cells co-localized with 
CD146 and NG2, two different markers display a similar role, which confirmed again 
that the traced cells from nestin positive lineage indeed develop into pericytes over 
time. 
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Figure 4.2.2 CD146 expression in the NesCreER
T2
 x Ai9-tdTomato mouse model. 
a. RFP (shown in red) and CD146 (shown in green) expression in tumor area of mouse brain 
samples from different groups (7 days and 21 days, 14 days not shown); b. Pictures from confocal 
microscopy indicated that after 21 days CD146 co-localized with RFP-expressing cells; c. RFP 
positive cells and RFP&CD146 double positive cells in tumor area were quantified from different 
groups; d, e. The percentage of RFP&CD146 double positive cells accounting for the total number 
of RFP positive cells (p<0.001), after 7 days, there were very few RFP positive cells co-localized 
with CD146, but after 21 days, most RFP positive cells co-localized with CD146, which indicated 
that the pericyte progenitor cells (RFP positive and CD146 negative) differentiate into pericytes 
(RFP positive and CD146 positive) during glioma expansion; f, g. RFP positive cells and 
RFP&CD146 double positive cells in peritumoral areas and contralateral hemisphere were 
quantified from different groups. Scale bars in a,b, 50 µm. 
a 
c d e 
f g 
b 
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4.2.3 Combined immunohistochemical staining for PDGFRß, NG2 and desmin 
As shown before, an increasing number of RFP positive cells express markers for 
pericytes during the time course of tumor development, but it was unclear whether the 
traced cells express different markers at the same time. To test this, mouse brain 
samples from the short-term group (7 days) and the long-term group (21 days) were 
stained and analyzed. Combinatorial staining for PDGFRß&NG2 or 
PDGFRß&desmin was performed. Confocal image analysis showed that throughout 
the time course of tumorigenesis increasing numbers of PDGFRß&NG2 or 
PDGFRß&desmin immunopositive cells co-localized with RFP positive cells (Figure 
4.2.3a, b). The number of RFP positive cells and immunopositive cells co-localizing 
with RFP were quantified. RFP&PDGFRß&NG2 or RFP&PDGFRß&desmin triple 
positive cells both significantly increased from 7 days to 21 days, and the percentage 
of triple positive cells accounting for the total amount of RFP-expressing cells in each 
group was similar (Figure 4.2.3c, d, j, h). After 21 days most of the RFP-expressing 
cells co-localized with two pericyte markers. However, after 7 days of tumor 
development only few RFP positive cells were immunostained for both pericyte 
markers. In the peritumoral area and the contralateral hemisphere almost no RFP& 
PDGFRß&NG2 or RFP&PDGFRß&desmin triple positive cells were observed 
(Figure 3.2.3e,f,I,j). 
 
 
 
 
 
39 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2.3 Combined staining for PDGFRß, NG2 and desmin in the 
NesCreER
T2
 x Ai9-tdTomato mouse model. 
a-b. RFP (shown in red), NG2 or desmin (shown in green) and PDGFRß (shown in 
blue) expression in tumor area of mouse brain samples from 21 days group; confocal 
pictures indicated that immunostaining for PDGFRß&NG2/desmin co-localized with 
RFP; c, g: RFP positive cells, RFP&PDGFRß&NG2 or RFP&PDGFRß&desmin 
triple positive cells in the tumor area were quantified from 7 days group and 21 days 
group; d, h: The percentage of RFP&PDGFRß&NG2 or RFP&PDGFRß&desmin 
triple positive cells accounting for the total number of RFP positive cells (p<0.001); 
e,f,i,j: The number of RFP positive cells and RFP&PDGFRß&NG2 or 
RFP&PDGFRß&desmin triple positive cells in the peritumoral area and the 
contralateral hemisphere were quantified. Scale bars in a,b, 200µm, a1,b1, 100µm. 
a 
c d 
e 
f 
g h 
i j 
b 
f 
a1 
b1 
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4.3 Comparative immunohistochemical characterization of the NesCreER
T2
-
 
tdTomato and JnesCreER
T2
-tdTomato mouse models 
In our study another mouse model named Jnes-CreER
T2 
Tdtomato was used except 
the Nes-CreER
T2
 Tdtomato mouse model. Many groups have created transgenic 
mouse models by combining nestin promoter of different spatial specificity with 
CreER
T2
 that allowing the temporal control of their activity [54]. The potential 
differences in efficiency and specificity between Nestin-CreER
T2
 and Jnes-CreER
T2
 
lines occurred for the combination of design. We can trace the sequence of CreER
T2
 
to the same research performed by Chambon and colleagues in both lines [50], but the 
construct of the nestin promoter in each line is significantly different [55]. To 
investigate the difference of the fate for traced cells between the Nes-CreER
T2
 and the 
Jnes-CreER
T2
 mouse models, a series of immunostainings were performed for the 
JnesCreER
T2
-tdTomato mouse samples.  
 
4.3.1 RFP expression in the NesCreER
T2
-tdTomato and JnesCreER
T2
-
 
tdTomato mouse models 
As explained above, RFP was used as a fate-mapping marker for nestin positive cells. 
In order to compare the expression of RFP in the tumor area of both transgenic mouse 
strains (NesCreER
T2 
or JnesCreER
T2
), the RFP positive cells were quantified in 
samples obtained after 14 days or 21 days of glioma genesis.  
 
The number of RFP positive cells in the tumor area also increases significantly from 
14 days to 21 days in the JnesCreER
T2
 transgenic mouse strain, but at both time points 
(14 days or 21 days) the number of RFP positive cells was much lower in the 
JnesCreER
T2
 mouse strain as compared to the NesCreER
T2
 mouse line (the 
differences at both time points are highly significant).  
41 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3.1 RFP expression in the NesCreER
T2
-tdTomato and JnesCreER
T2
-
 
tdTomato mouse models 
 
a. RFP positive cells (shown in red) in the tumor area from NesCreER
T2 
and 
JnesCreER
T2
 mouse strains in 14 days and 21 days;  b, c. Quantification of RFP 
positive cells in the tumor area from NesCreER
T2 
and JnesCreER
T2
 groups , at both 
time points the number of RFP positive cells in the JnesCreER
T2
 mouse strain was 
much lower as compared to the NesCreER
T2
 mouse strain (p<0.001). Scale bars in a, 
200µm. 
 
 
 
 
 
 
 
 
 
a 
c 
b 
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4.3.2 Investigation for the fate of RFP positive cells in the 
JnesCreER
T2
-tdTomato mouse model. 
 
In NesCreER
T2
-tdTomato mice, most of the traced cells (RFP positive cells) expressed 
pericytes markers (such as NG2, PDGFRß, desmin or CD146) after 21 days of tumor 
growth (see Fig.4.2.1- 4.2.3), but in the JnesCreER
T2
-tdTomato mouse model the 
co-localization with pericyte markers remained to be determined. To observe this, 
immunostainings for pericyte markers NG2 and PDGFRß were performed for the 
JnesCreER
T2
 mouse samples (Figure 4.3.2 a,b). RFP positive cells, RFP&NG2 double 
positive cells and RFP&PDGFRß double positive cells were quantified (Figure 4.3.2 
c-d), there was no pericyte marker co-localized with RFP positive cells in mice of the   
JnesCreER
T2 
strain. These data show that only the NnesCreER
T2
-tdTomato mouse 
strain is a lineage tracing model for pericytes, while the JnesCreER
T2
-tdTomato 
mouse line is not indicating cells acquiring a pericyte cell-fate. 
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Figure 4.3.2 NG2 and PDGFRß expression in the NesCreER
T2
-tdTomato and 
JnesCreER
T2
-tdTomato mouse models  
a-b: RFP (shown in red) and NG2 or PDGFRß (shown in green) expression in the 
tumor area of mouse brain samples from NesCreER
T2 
or JnesCreER
T2
 group (21 days 
tumor growth); c-d: RFP&NG2 or RFP&PDGFRß double positive cells in the tumor 
area were quantified from both groups, there was no RFP positive cells co-localized 
with NG2 or PDGFRß in JnesCreER
T2
 mouse group. Scale bars in a,b, 200µm. 
a b 
c d 
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4.3.3 GFAP expression in the NesCreER
T2
-tdTomato and JnesCreER
T2
- 
tdTomato mouse models 
To investigate the fate of cells traced by the JnesCreER
T2
-tdTomato mouse model, 
another series of immunohistochemical experiments was performed. Here it was 
observed that RFP-expressing cells in the JnesCreER
T2
 mouse strain co-localized with 
glial fibrillary acidic protein (GFAP). GFAP is an intermediate filament protein which 
is expressed by astrocytes in the central nervous system [56, 57]. GFAP positive cells 
play an important role in many processes of central neural system, such as the 
formation of blood brain barrier and cell communication [58]. GFAP expression in the 
peritumoral area was much higher than in the tumor area (Figure 4.3.3 a), RFP 
positive cells as well as RFP&GFAP double positive cells were quantified both in the 
tumor area and peritumoral area (Figure 4.3.3 b). Comparing the percentage of 
RFP&GFAP double positive cells accounting for RFP positive cells between tumor 
area and peritumoral area, there is a small but significant increase of the percentage of  
RFP&GFAP double positive cells in peritumor area (Figure 4.3.3 c, p<0.05).  
 
Immunostaining for GFAP was also performed in NesCreER
T2
-tdTomato mouse brain 
samples, similar to the JnesCreER
T2
 mouse group, GFAP expression was also detected 
mostly surrounding the tumor area (Figure 4.3.3 d). Unlike the JnesCreER
T2
 mouse 
model, there were almost no RFP positive cells co-localized with GFAP both in the 
tumor area or peritumoral area (Figure 4.3.3 e)，and there was a significant difference 
of the percentage of RFP&GFAP double positive cells as compared to JnesCreER
T2
 
mouse group both in the tumor area or peritumoral area (Figure 4.3.3 f, g, p<0.001). 
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Figure 4.3.3 GFAP expression in the NesCreER
T2
-tdTomato and JnesCreER
T2 
-tdTomato mouse models 
a,d. RFP (shown in red) or GFAP (shown in green) expression in tumor area of mouse 
brain samples from NesCreER
T2 
and JnesCreER
T2
 groups (14 days); b,e. RFP positive 
cells and RFP&GFAP double positive cells were quantified from both groups; f-g. 
The percentage of RFP&GFAP double positive cells in JnesCreER
T2
 group is 
significantly higher than NesCreER
T2
 group both in tumor area and peritumoral area 
(P<0.001). Scale bars in a,d, 200µm, 300µm. 
b a
c 
e 
f g 
d 
Tumor area 
Tumor area 
Tumor area 
Tumor area 
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4.4 Immunohistochemical characterization of cells traced in the 
NesCreER
T2
-tdTomato mouse model in a postnatal development 
 
To further investigate the lineage of nestin positive cells in the NesCreERT2- 
tdTomato mouse strain, gene recombination was induced after birth (at postnatal day 
0; P0), and the mice were sacrificed after 3 weeks (p21). The brain tissues were 
harvested for immunohistochemical analysis.  
 
4.4.1 RFP expression in the NesCreER
T2
 Tdtomato mouse model in the postnatal 
brain
 
RFP positive cells were quantified in the cortex, striatum and brain stem (Fig 4.4.1 a). 
When comparing the numbers of RFP-positive cells in these 3 brain areas no 
difference was detected (Figure 4.4.1 b). The morphology of the RFP positive cells 
was heterogeneous; the majority displayed a vascular, pericyte-like morphology, 
indicating that they may develop into pericytes. 
  
 
 
 
 
 
Figure 4.4.1 RFP expression in the NesCreER
T2
-tdTomato pups (P 21) 
a. RFP (shown in red) expression in the brain (cortex, striatum and brain stem) of 
NesCreERT2-tdTomato pups; b. RFP positive cells were quantified from cortex, 
striatum and brain stem, there was no difference in the number of RFP positive cells 
among the 3 areas. 
a b 
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4.4.2 Perivascular location of RFP-positive cells 
To investigate if the traced cells acquired a perivascular-cell fate, immunofluorescence 
labelling for Von Willebrand factor (VWF), a blood glycoprotein that is considered to 
be important for hemostasis and represents a specific markers for endothelial cells [59] 
was performed. Staining with Isolectin-B4 (IB4) which can be used to label 
endothelial cells, microglia and macrophages was carried out. Most RFP-expressing 
cells were located near vascular structures (Figure 4.4.2). Staining with the pericyte 
marker PDGFRß showed that RFP-expressing cells located close to blood vessels and 
co-localized with PDGFRß (Figure 4.4.3), which indicated that the cells traced with 
the NesCreERT2-tdTomato mouse model over a postnatal period develop into 
pericytes. Importantly, this indicates that the NesCreERT2-tdTomato strain is a useful 
model to trace the pericyte lineage both in pathological neoangiogenesis during 
glioma growth and in physiological postnatal angiogenesis. 
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Figure4.4.2 Vascular markers (VWF and IB4) expression in the NesCreERT2- 
tdtomato postnatal mouse brain (P 21). 
 
a. RFP (shown in red) and vascular markers VWF and IB4 (shown in green) 
expression in NesCreERT2-tdTomato postnatal mouse brain (P21); Scale bars in a, 
50µm. 
 
  
a 
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4.4.3 Investigating the fate of RFP-positive cells in the NesCreER
T2
- 
tdTomato mouse model in postnatal brain development 
The morphology and location of RFP-positive cells indicated that there is genesis of 
pericytes from the nestin positive linage. The mouse brain samples were stained with 
pericyte markers such as NG2, PDGFRß or desmin, and the analysis of 
co-localization of RFP positive cells with the pericyte markers was performed by 
confocal microscopy. 
 
The data showed that at the postnatal day 21 (P21) many RFP-expressing cells 
expressed PDGFRß (Figure 4.4.3 a), confocal image analysis showed that RFP 
positive cells co-localized with PDGFRß (Figure 4.4.3b). The numbers of RFP 
positive cells and RFP&PDGFRß double positive cells were quantified (Figure 4.4.3 
c), and the percentage of RFP&PDGFRß double positive cells accounting for total 
RFP positive cells was around 30% (Figure 4.4.3 d). Comparing the percentage of 
RFP&PDGFRß double positive cells in cortex, striatum and brain stem, there is a 
slight increase for the percentage of RFP&PDGFRß double positive cells in cortex, 
and there was no difference for the percentage between striatum and brain stem 
(p>0.05, Figure 4.4.3 e). Immunostainings for desmin and NG2 were also performed. 
The result showed that PDGFRß expression in the brain is significantly higher than 
the expression of desmin or NG2 (p<0.01, Figure 4.4.3 f). These findings indicated 
that many cells traced in the NesCreERT2-tdTomato mouse model at postnatal time 
point (P21) develop into pericytes. 
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Figure 4.4.3 Pericyte marker expression in the NesCreER
T2
-tdTomato postnatal  
mouse brain (P21). 
a. RFP (shown in red) and PDGFRß (shown in green) expression in mouse brain 
samples from NesCreER
T2
-Tdtomato pups (P21); b. Pictures from confocal 
microscopy indicated that PDGFRß co-localized with RFP-expressing cells; c-d. RFP 
positive cells and RFP&PDGFRß double positive cells were quantified; e.        
The percentage of PDGFRß expression in different area of the brain in nes-CreER
T2
 
Tdtomato postnatal mice (P21) was calculated, the expression of PDGFRß in cortex is 
slightly higher than striatum or brain stem (0.01p<0.05); f. The percentage of different 
pericyte markers expression in the brain of nes-CreER
T2
 Tdtomato postnatal mice 
(P21) was calculated, at the same time point, the expression of PDGFRß is much 
more abundant in RFP positive cells than NG2 or desmin (P<0.01). Scale bar in a, 
100µm. 
a 
b 
c 
d 
e f. 
51 
 
4.4.4 Myeloid marker investigation 
As shown above, the RFP positive cells expressed pericyte markers during postnatal 
brain development, some previous research suggested that microglia may derive from 
pericytes in the brain, for example, Monteiro et al demonstrated that microglia may 
derive from pericytes in rat cerebellar cortex [60]. In order to investigate whether the 
RFP positive cells express the myeloid lineage markers, Iba1 immunofluorescence 
staining was performed. As shown in Figure 4.4.4, there are no RFP positive cells 
co-localized with Iba1, indicating that in our study the RFP-positive pericytes do not 
develop into microglia. 
 
 
 
 
 
 
 
 
 
 
 
Figure4.4.4 Iba1 expression in the NesCreER
T2
-tdtomato postnatal mouse brain 
 (P 21). 
RFP (shown in red) and Iba1 (shown in green) expression in the NesCreERT2- 
tdTomato postnatal mouse brain (P 21), there is no RFP positive cells co-localized 
with Iba1. Scale bar, 50µm. 
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4.4.5 Glial marker investigation in the pericyte-reporter mouse model 
 
To investigate whether the traced cells develop into glial cells, immunofluorescence 
staining for GFAP was performed and subsequently samples were analyzed by 
confocal laser scanning microscopy. This staining showed that the RFP positive cells 
do not express GFAP, but are in close apposition to perivascular astrocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure4.4.5 GFAP expression in the NesCreER
T2
-tdtomato postnatal mouse brain 
 (P 21). 
 
RFP (shown in red) and GFAP (shown in green) expression in the NesCreERT2- 
tdTomato postnatal mouse brain (P 21), there are no RFP positive cells co-localized 
with GFAP. Scale bar, 50µm. 
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4.4.6 RFP positive cells develop into pericytes of the retina in physiological 
condition 
In our study the fate of RFP positive cells in retina was also traced in the 
NesCreERT2-tdTomato postnatal mice. At postnatal day 21, the pericytes were 
detected in the developing retina vasculature (Fig. a, b, the brown arrow). 
Immunostainings for the pericyte marker NG2 and the endothelial cell marker CD31 
were performed (Fig. c, d), which showed that the RFP positive cells co-localized 
with NG2 and were located in a perivascular position, indicating that the RFP positive 
cells develop into pericytes of the retina under physiological condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.4.6 Vascular development in the retina. 
a-b. pericytes (PC, the brown arrow) were shown in the ultrastructure of the 
developing retina vasculature; c-d. RFP (shown in red), NG2 (shown in green) and 
CD31 (shown in blue) expression in mouse retina from NesCreER
T2
-Tdtomato pups 
(P21), the RFP positive cells co-localized with pericyte marker NG2 and located in a 
perivascular position. 
a b 
c d 
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5. Discussion 
In this study we established a GL261 high-grade glioma mouse model in immune 
competent transgenic Nes-CreER
T2 
Tdtomato mice that allowed tracing the fate of 
nestin-expressing cells. We chose the GL261 mouse glioma model because it is 
syngeneic with the transgenic mouse model used in this study and faithfully 
recapitulate some pathological relevant features of GBM [61]. During the intracranial 
tumor growth, a significant increase in the number of RFP positive cells was observed 
and these RFP-positive cells co-localized with different pericyte markers (such as 
NG2, desmin, PDGFRß and CD146). After 7 days of tumor progression, few 
RFP-positive cells co-localized with pericye marker, whereas after 21 days of tumor 
growth most of the RFP-positive cells were immunofluorescently labelled with 
pericyte markers, which indicated that the pericyte progenitor cells (RFP positive and 
pericyte marker negative cells) developed into mature pericytes (RFP positive and 
pericyte marker positive cells) during the tumor expansion. The accumulation of new 
pericytes was most abundant within the tumor, but not in the peritumoral area or 
contralateral hemisphere, indicating that new pericytes derive from pericyte 
progenitor cells of the adult brain mainly during neo-angiogenesis. In another 
transgenic mouse model with a genetically different nestin construct 
(Jnes-CreER
T2
Tdtomato mouse), we also traced intratumoral cells and these cells 
were found to express astrocyte markers like GFAP but not pericyte markers. Overall, 
our study shows that pericytes play an important role in brain tumor angiogenesis, and 
confirms that pericyte can provide a new target for anti-angiogenesis in brain cancer. 
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In our study we also used the transgenic Nes-CreER
T2
Tdtomato mouse model to trace 
the fate of nestin-expressing cells in the tumor-free brain over postnatal period. We 
found that the traced cells distributed in the entire brain, many of which displayed a 
perivascular morphology and also expressed pericytes markers in the brain and retina 
(during an observation period of 21 days), indicating that the pericyte-progenitor cells 
marked by nestin-creER
T2
 mouse strain specifically trace brain-pericytes. This 
suggests an important physiological role of pericyte progenitors in brain development. 
 
5.1 The pericyte progenitor cell  
Pericytes play an important role in angiogenesis, but the origin of pericytes is still 
poorly understood. Some previous studies claimed the identification of a pericyte 
progenitor cell type, for example Steven Song et al showed that tumor derived 
PDGFRß+ perivascular progenitor cells have the ability to develop into pericytes in 
pancreatic carcinoma and a subset of PDGFRß+ pericyte progenitor cells are recruited 
from the bone marrow [62]. In this study a PDGFRß, desmin, NG2 and CD146 
negative pericyte progenitor cell type was uncovered in glioma angiogenesis. 
Therefore, we established a GL261 high-grade glioma mouse model in transgenic 
Nes-CreER
T2 
Tdtomato mice to trace the fate of nestin-expressing cells and their 
progeny in the mouse brain. During the intracranial tumor growth, a significant 
increase in the number of RFP positive cells was observed. In the early time course (7 
days of tumor growth) few RFP-positive cells co-localized with pericye markers, 
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whereas in the later time course (21 days of tumor growth) most of the RFP-positive 
cells expressed pericyte markers like PDGFRß, desmin, NG2 and CD146. These 
findings indicated that pericyte progenitor cells (RFP positive and pericyte marker 
negative cells) differentiated into mature pericytes (RFP positive and pericyte marker 
positive cells) during tumor expansion. These date showed that the new pericytes in 
glioma derived from pericyte progenitor cells (defined as RFP positive and pericyte 
marker negative cells) in the Nes-CreER
T2 
Tdtomato mouse model. In another 
transgenic mouse model with a different transgenic nestin-promoter element called 
JnesCreER
T2 
Tdtomato mouse model, we also traced the intratumoral RFP positive 
cells and these cells were found to express astrocyte markers like GFAP but not 
pericyte markers. Neural stem cells are capable of differentiating into astrocytes, 
neurons and oligodendroglia cells [63, 64], which indicates that the traced cells in 
JnesCreER
T2 
Tdtomato mouse model originate from neural stem cells. Taken together, 
the traced cells in Nes-CreER
T2 
Tdtomato mouse model express pericyte markers but 
not GFAP, indicating that the traced cells are pericyte progenitor cells; while the 
traced cells in JnesCreER
T2 
Tdtomato mouse model express GFAP but not pericyte 
markers, indicating that the traced cells derive from neural stem cells. 
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5.2 The role of pericytes in glioblastoma  
Our findings from the Nes-CreER
T2
-Tdtomato mouse model showed that new 
pericytes were accumulated specifically within the intracranial glioma, indicating that 
pericytes play an important role in brain tumor angiogenesis. As introduced before, 
the different functions of pericytes include maintenance of the BBB/Blood-Retina 
-Barrier (BRB), vessel-formation and vessel-maturation, angiogenesis and contractile 
function. Pericytes were considered as an important component of the glioblastoma 
vasculature, the tumor pericytes are able to facilitate tumor growth by promoting 
endothelial cell survival [65, 66] and mediating immunosuppression [67]. The origin 
of pericytes in glioblastoma is still a controversial issue. It was suggested that 
glioblastoma stem cells within the tumor itself generated the majority of new 
pericytes [68] or the pericytes in the tumor were derived from the bone marrow [69]. 
Furthermore, Daniel Bexell et al demonstrated that bone marrow–derived 
mesenchymal stromal cells (MSCs) share characteristics of pericytes in GBMs such 
as a strong tumor tropism, expression of pericyte markers (SMA, NG2 or PDGFRß) 
and integration into the tumor vessel wall [70]. In our study we showed that the 
pericyte progenitor cells differentiated into pericytes during the tumor expansion, the 
accumulation of new pericytes was observed mainly within the tumor, but not in the 
peritumoral area or contralateral hemisphere. Surprisingly, those newly formed 
pericytes appear to originate from a pericyte progenitor cell-type that may be 
endogenous to the brain as no td-Tomato positive cells were found in other organs 
(not shown). 
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Though previous research defined many molecular regulators which are important for 
pericyte activation and function [71], the mechanism of pericytes activation and 
recruitment after local tumor growth is not yet fully elucidated. There is a series of 
pathological alterations in the microenvironment of the brain throughout tumor 
growth, including the formation of hypoxic areas, edema and strong angiogenesis 
with many vascular malformations [33, 72, 73]. During glioma expansion more and 
more new pericytes will be recruited to participate in the formation of new vessels and 
play a crucial role in glioma angiogenesis.  
Glioblastomas (GBMs) are highly aggressive tumors and rich in blood vessels, which 
can also provide a path for tumor invasion [74]. The major anti-angiogenic therapies 
for GBMs focus on targeting endothelial cells alone by blocking vascular endothelial 
growth factor (VEGF) signaling. However, though current anti-VEGF therapies are 
beneficial for some patients with cancer, VEGF-blockade does not improve overall 
survival of GBM patients [75]. Furthermore, anti-angiogenic therapies have the 
potential to trigger a more aggressive and metastatic phenotype in GBMs [76, 77], 
suggesting that anti-angiogenic therapy of targeting endothelial cells alone is not 
sufficient to control tumor progression effectively. In addition to endothelial cells, 
Pericytes are also an important component of tumor vessels [78]. Pericytes interact 
with endothelial cells and both control tumor vessel growth and integrity [79]. 
Moreover, pericytes can promote the resistance to anti-VEGF therapies by activating 
the PDGF receptor signaling pathway to protect the endothelial cells [77, 80]. 
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Therefore, pericytes can provide a new target for anti-angiogenesis in brain cancer, 
and targeting endothelial cells and pericytes simultaneously might make 
anti-angiogenic therapy more effective. 
 
5.3 The role of pericytes in vascular development of the retina 
In our study RFP-expressing pericyte marker positive cells were not only detected in 
glioma-induced angiogenesis in the adult brain, but also in the postnatal mouse retina, 
indicating that RFP-traced pericytes play an important role in both physiological and 
pathological angiogenesis. The density of pericyte changes from organ to organ, it is 
reported that the highest relative ratio of pericytes to endothelial cells is detected in 
the retina and the brain, where the endothelial cell to pericyte ratio is 1:1, while it is 
often much lower in peripheral organs (like 1:100) [24, 81]. The arteries and arterioles 
of the retina are covered by vascular smooth muscle cells (vSMCs), whereas 
capillaries of the retina are covered by pericytes [82]. In the last two decades, 
pericytes were considered to be a primary component of the BRB. The BRB consists 
of the inner BRB (provided by the retinal vascular endothelium) and the outer BRB 
(which consists of retinal pigment epithelium) [82, 83]. Like the BBB, the BRB is a 
highly efficient regulated barrier, it can prevent the entry of potentially harmful 
substances to the CNS and guards the homeostasis of the neuronal microenvironment 
[84]. Though the structure of the Blood-Brain-Barrier is similar to the inner BRB [85], 
some studies showed that between brain and the neurovascular unit of the retina there 
is heterogeneity in transport properties [86]. Up to now, many studies have shown that 
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pericyte loss results in BBB breakdown and increases vascular permeability: by 
establishing a mouse model with PDGFRß signaling deficiency , Bell et al 
demonstrated that after reducing the coverage of pericytes in the brain, the BBB was 
damaged and a lot of plasma derived proteins accumulated in the CNS, finally leading 
to secondary neuronal degenerative alterations [33].There were also some studies that 
investigated the changes in neuronal function and BRB permeability under conditions 
when pericyte coverage was reduced. After endothelium-specific platelet-derived 
growth factor-B ablation mice, Enge et al demonstrated that reduced pericyte 
coverage in capillaries led to a fast pathologic progression in diabetic retinopathy [43]. 
Furthermore, pericytes can promote the formation of tight junctions in developing 
retinal vasculature in postnatal mice [87]. 
A reduced vessel coverage and altered function of pericytes can be causally involved 
in certain CNS diseases [88]. Diabetes mellitus refers to a group of metabolic diseases 
and diabetic retinopathy (DR) is one major complication. The characterization of DR 
includes progressive vascular occlusion, Blood-Retina-Barrier breakdown, increased 
vascular permeability and neuronal damage finally leading to a serious visual 
impairment [89]. Though during the pathologic progression of DR pericyte loss is 
considered as a well-established fact, the potential mechanisms of DR is still not clear 
[90]. Pericyte loss through apoptosis has been suggested, which is associated with 
hyperglycemic conditions, neuro inflammation, reduced trophic factor signaling, 
oxidative stress and glutamate receptor excitation [91, 92]. Up to now, substantial 
research has been devoted to investigating the underlying mechanisms of vascular 
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leakage and pericyte loss in DR, but the reasons for BRB breakdown still remain 
unclear [43, 93]. In summary, pericytes play an indispensable role in the formation 
and the stability of BRB, pericyte deficiency leads to pathological progression of 
diverse CNS diseases, pericytes can provide a promising target for regenerative 
therapeutic approaches in the future.   
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6. Summary  
 
The current study established that a transgenic mouse model, Nes-CreER
T2  
Tdtomato, 
is of use to trace the fate of nestin-expressing cells in glioma progression and 
postnatal brain development. Through a series of cell type identification tests, using 
immunofluorescence labelling and confocal microscopy, it was shown that these 
nestin-positive cells generate new pericytes, but initially do not have a pericyte 
identity, this is corroborated by the following findings: 
 
(1) In the Nes-CreER
T2 
Tdtomato mouse model, the number of traced cells (RFP 
positive cells) increased during the intracranial tumor growth. At an early time point 
(7 days) few of the RFP positive cells co-localized with pericyte markers while at a 
later time point (21 days) most of the RFP positive cells co-localized with pericyte 
markers, which indicated that the new pericytes in glioma derived from the pericyte 
progenitor cells (defined as RFP positive and pericyte marker negative cells) in the 
Nes-CreER
T2 
Tdtomato mouse model; 
(2) In the JnesCreER
T2 
Tdtomato mouse model, the traced cells were found to express 
astrocyte-markers like GFAP but not pericyte markers, which indicated that the traced 
cells in the JnesCreER
T2 
Tdtomato mouse model were originally neural stem cells 
rather than pericyte progenitor cells. Hence, only the Nes-CreER
T2 
Tdtomato mouse 
model is useful to study pericyte development in the brain. 
(3) The cells traced with the NesCreERT2-tdTomato mouse model over a postnatal 
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period develop into pericytes in the brain, which indicates that the 
NesCreERT2-tdTomato strain is a useful model to trace the pericyte lineage both in 
pathological neoangiogenesis during glioma growth and in physiological postnatal 
angiogenesis. 
(4) In this study RFP-expressing pericyte marker positive cells were detected in the 
postnatal mouse retina, indicating that RFP-traced pericytes play an important role in 
both pathological angiogenesis and physiological vascular development of retina. 
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Zusammenfassung  
 
Die vorliegende Doktorarbeit zeigt, dass das NesCreERT2 TdTomato Maus Modell 
verwendet werden kann, um ein Lineage-Tracing von Zellen aus der Nestin positiven 
Linie während des Gliom-Wachstums und der postnatalen ZNS-Entwicklung 
durchzuführen. Anhand einer Reihe von Zelltyp-Identifizierungs-Tests mithilfe von 
Immunfluoreszenz und Konfokalmikroskopie wurde gezeigt, dass sich diese 
Nestin-positiven Zellen zu neuen Perizyten entwickeln, allerdings initial keine 
Perizyten-Marker tragen. Dies wird durch folgende Ergebnisse verdeutlicht:  
 
(1) Im NesCreERT2 TdTomato Maus Modell nahm die Anzahl der Zellen aus der 
Nestin positiven Linie (RFP positive Zellen) während des intrakraniellen 
Tumorwachstums zu. Zu einem frühen Zeitpunkt (7 Tage) co-lokalisierten wenige der 
RFP positiven Zellen mit Perizyten-Markern, während zu einem späteren Zeitpunkt 
(21 Tage) die meisten der RFP positiven Zellen mit Perizyten-Markern 
co-lokalisierten. Dies weist darauf hin, dass im NesCreERT2 TdTomato Maus Modell 
neue Perizyten innerhalb von Gliomen von Perizyten-Vorläufer-Zellen (definiert als 
RFP-positive und Perizyten-Marker-negative Zellen) abstammen. 
 
(2) Im JnesCreERT2 TdTomato Maus Modell exprimierten die Zellen aus der Nestin 
positiven Linie Astrozyten-Marker wie beispielsweise GFAP, aber keine 
Perizyten-Marker, was darauf hindeutet, dass diese im JnesCreERT2 TdTomato Maus 
Modell ursprünglich Neuronale Stammzellen darstellten, allerdings keine 
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Perizyten-Vorläufer-Zellen. Entsprechend kann nur das NesCreERT2 TdTomato Maus 
Modell, nicht jedoch das JnesCreERT2 TdTomato Maus Modell, für eine Analyse der 
Perizyten-Entwicklung im zentralen Nervensystem verwendet werden.  
 
(3) Im NesCreERT2 TdTomato Maus Modell entwickelten sich die Zellen aus der 
Nestin positiven Linie postnatal zu Perizyten im zentralen Nervensystem. Dies deutet 
darauf hin, dass besagtes Maus Modell für ein Lineage-Tracing von Perizyten 
verwendet werden kann, sowohl während pathologischer Neoangiogenese im Kontext 
des Gliom-Wachstums als auch während physiologischer postnataler Angiogenese. 
 
(4) Im Rahmen der vorliegenden Arbeit wurden RFP-exprimierende, 
Perizyten-Marker-positive Zellen in postnatalem, murinen Retinagewebe gefunden, 
was verdeutlicht, dass RFP-positive Perizyten sowohl bei pathologischer Angiogenese 
als auch bei der physiologischen Vaskularisierung der Retina eine wichtige Rolle 
spielen.  
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